Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide

NICE Evidence Summary, February 2017

Glycopyrronium bromide (Sialanar) is an antimuscarinic (anticholinergic) medicine licensed in September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Sialanar is licensed for short-term intermittent use and is only licensed in children. There is limited clinical trial evidence on the use of glycopyrronium in adults with sialorrhoea. Sialanar 320 micrograms/ml oral solution is the first formulation of glycopyrronium bromide licensed for this indication in the UK.

Link to NICE Evidence Summary

Improving outcomes for children and families in the early years: a key role for health visiting services

improving-outcomes-health-visiting

In 2015 health visiting was brought into the local government fold for the first time since 1974.

As with so much of public health, the move into local government offers fresh opportunities. By integrating health visiting with other services, such as children’s centres, early help, safeguarding and public health teams, we can provide better support to children and their families.

These case studies demonstrate examples of innovation. But there have also been challenges. Concerns have been raised that in some areas health visitor posts are being cut as a consequence of the reductions to local government funding.

The cuts to local authority public health budgets make it more important than ever for health visitors and commissioners to work together to monitor and evaluate the impact of the service.

Link to document pdf here